Trial record 1 of 2 for:
olaparib | Pancreatic cancer | United Kingdom
Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00515866 |
Recruitment Status :
Completed
First Posted : August 14, 2007
Last Update Posted : December 20, 2013
|
Sponsor:
AstraZeneca
Information provided by (Responsible Party):
AstraZeneca
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | October 2011 |
Actual Study Completion Date : | July 2012 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):